KR20150107742A - 흑색종 세포를 퇴치하기 위한 델피니딘 - Google Patents

흑색종 세포를 퇴치하기 위한 델피니딘 Download PDF

Info

Publication number
KR20150107742A
KR20150107742A KR1020157018732A KR20157018732A KR20150107742A KR 20150107742 A KR20150107742 A KR 20150107742A KR 1020157018732 A KR1020157018732 A KR 1020157018732A KR 20157018732 A KR20157018732 A KR 20157018732A KR 20150107742 A KR20150107742 A KR 20150107742A
Authority
KR
South Korea
Prior art keywords
delphinidin
cells
cell
sbe
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157018732A
Other languages
English (en)
Korean (ko)
Inventor
노르베르트 로위
옌스 브로스키트
Original Assignee
자피오텍 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자피오텍 게엠베하 filed Critical 자피오텍 게엠베하
Publication of KR20150107742A publication Critical patent/KR20150107742A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A61K47/48969—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
KR1020157018732A 2012-12-11 2013-11-28 흑색종 세포를 퇴치하기 위한 델피니딘 Withdrawn KR20150107742A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012222777 2012-12-11
DE102012222777.6 2012-12-11
EP13150909 2013-01-11
EP13150909.3 2013-01-11
PCT/EP2013/074991 WO2014090586A1 (de) 2012-12-11 2013-11-28 Delphinidin zur bekämpfung von melanomzellen

Publications (1)

Publication Number Publication Date
KR20150107742A true KR20150107742A (ko) 2015-09-23

Family

ID=49679524

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157018732A Withdrawn KR20150107742A (ko) 2012-12-11 2013-11-28 흑색종 세포를 퇴치하기 위한 델피니딘
KR1020157018731A Expired - Fee Related KR102164174B1 (ko) 2012-12-11 2013-11-28 흑색종 세포를 퇴치하기 위한 델피니딘

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157018731A Expired - Fee Related KR102164174B1 (ko) 2012-12-11 2013-11-28 흑색종 세포를 퇴치하기 위한 델피니딘

Country Status (8)

Country Link
US (2) US9949947B2 (https=)
EP (2) EP2931286B1 (https=)
JP (2) JP6234475B2 (https=)
KR (2) KR20150107742A (https=)
CN (2) CN104936601A (https=)
CA (2) CA2893881C (https=)
HK (1) HK1215392A1 (https=)
WO (2) WO2014090583A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946228A (ja) 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8907008D0 (en) 1989-03-28 1989-05-10 Inverni Della Beffa Spa Intermediates useful for the synthesis for delphinidin chloride
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
GB2307176A (en) 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
JP4101346B2 (ja) 1998-02-18 2008-06-18 ダイセル化学工業株式会社 酸化触媒系及びそれを用いた酸化方法
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
AU6527300A (en) 1999-08-11 2001-03-05 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
AU7937500A (en) 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
ES2250460T3 (es) 2000-09-12 2006-04-16 Meiji Seika Kaisha, Ltd. Procedimiento para la preparacion de glucosido de antocianidina purificado.
JP4334229B2 (ja) 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003171274A (ja) 2001-12-07 2003-06-17 Tomihiko Higuchi 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
BR0307518A (pt) 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
JPWO2005067905A1 (ja) 2004-01-14 2007-12-27 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
CN1317961C (zh) 2004-03-25 2007-05-30 吴朝琴 冻干草莓加工工艺
CN100342026C (zh) 2004-05-13 2007-10-10 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
DE102005017775A1 (de) 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
KR100733913B1 (ko) * 2005-08-30 2007-07-02 한국화학연구원 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
WO2008070490A2 (en) 2006-11-28 2008-06-12 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR100756656B1 (ko) 2006-12-12 2007-09-10 한국화학연구원 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품
KR100880876B1 (ko) 2007-04-11 2009-01-30 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
JP5574600B2 (ja) 2007-12-17 2014-08-20 日本製薬工業株式会社 吸収性骨疾患の予防・治療剤
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20120083460A1 (en) 2009-03-25 2012-04-05 San Ei Gen F.F.I., Inc. Readily water-soluble isoquercitrin composition
EP2437770A4 (en) 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
EP2344154B1 (en) 2009-10-21 2016-12-07 Maqui New Life S.A. Compositions that include anthocyanidins and methods of use
EP2345427A1 (de) 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
CN102892310B (zh) 2010-03-13 2016-07-06 伊斯顿庞德实验室有限公司 结合脂肪的组合物
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
AU2010366535A1 (en) 2010-12-31 2013-07-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
DK2484350T3 (en) 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
CA2869056C (en) 2012-03-30 2020-02-25 Sapiotec Gmbh Anthocyanidin complex
JP6193970B2 (ja) 2012-03-30 2017-09-06 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対するデルフィニジンの使用
CN104780925A (zh) 2012-10-17 2015-07-15 赛博尔泰克股份公司 用于治疗多发性骨髓瘤的花青素络合物
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2913366A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes

Also Published As

Publication number Publication date
WO2014090586A1 (de) 2014-06-19
KR20150107741A (ko) 2015-09-23
JP2016502985A (ja) 2016-02-01
US9511047B2 (en) 2016-12-06
CN104936601A (zh) 2015-09-23
HK1215392A1 (zh) 2016-08-26
JP6234476B2 (ja) 2017-11-22
JP6234475B2 (ja) 2017-11-22
EP2931286A1 (de) 2015-10-21
EP2931287B1 (de) 2017-10-04
KR102164174B1 (ko) 2020-10-12
JP2016502984A (ja) 2016-02-01
CA2893881C (en) 2020-09-22
HK1216229A1 (zh) 2016-10-28
US9949947B2 (en) 2018-04-24
CA2893883A1 (en) 2014-06-19
US20150320719A1 (en) 2015-11-12
EP2931287A1 (de) 2015-10-21
CN104918622A (zh) 2015-09-16
WO2014090583A1 (de) 2014-06-19
US20150328336A1 (en) 2015-11-19
EP2931286B1 (de) 2017-10-04
CA2893881A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
Zhang et al. Targeting ferroptosis by polydopamine nanoparticles protects heart against ischemia/reperfusion injury
Tang et al. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer
Qiu et al. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells
Liang et al. Copper-coordinated nanoassemblies based on photosensitizer-chemo prodrugs and checkpoint inhibitors for enhanced apoptosis-cuproptosis and immunotherapy
Liang et al. Intratumoral injection of thermogelling and sustained-release carboplatin-loaded hydrogel simplifies the administration and remains the synergistic effect with radiotherapy for mice gliomas
Luo et al. An albumin-binding dimeric prodrug nanoparticle with long blood circulation and light-triggered drug release for chemo-photodynamic combination therapy against hypoxia-induced metastasis of lung cancer
Tarannum et al. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer
Zheng et al. Self-delivery nanomedicine to overcome drug resistance for synergistic chemotherapy
Huang et al. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma
Zhou et al. Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy
Wu et al. Fluorescent hyaluronic acid nanoprodrug: A tumor-activated autophagy inhibitor for synergistic cancer therapy
Huang et al. Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis
CN101537185A (zh) 一种肿瘤细胞主动靶向载药系统及其制备方法和应用
KR102164174B1 (ko) 흑색종 세포를 퇴치하기 위한 델피니딘
Li et al. Protective effects of Prussian blue nanozyme against sepsis-induced acute lung injury by activating HO-1
CN110101685A (zh) 一种仿生纳米药物、其制备方法及应用
Menezes et al. Analysis in vivo of antitumor activity, cytotoxicity and interaction between plasmid DNA and the cis-dichlorotetraammineruthenium (III) chloride
US12128111B2 (en) Glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and preparation method thereof
KR20150070303A (ko) 다발성 골수종 치료를 위한 안토시아니딘 복합제
Zhao et al. Simultaneous inhibition of heat shock proteins and autophagy enhances radiofrequency ablation of hepatocellular carcinoma
Zhang et al. A multifunctional injectable MPDA@ MTIC–Co hydrogel platform for synergistic chemotherapy–photothermal therapy of postoperative glioblastoma
Dewi et al. Improving the Anticancer Efficacy of Tetrahydrocurcumin via β‐Cyclodextrin Inclusion Complexation
HK1216229B (en) Delphinidin for combating melanoma cells
Xue et al. Copper/iron-based intelligent nanoparticles self-amplify apoptosis/ferroptosis/cuproptosis in colorectal cancer
Shin et al. Anti-cancer Activities of Anthocyanins of Vitis Coignetiae Pulliat in Human Hepatocelluar Carcinoma Cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid